CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 966edf82-6b1e-4214-8625-15d80ed50795
exploratory
The cited A/B receipts support a specific working claim: Telomeres length of T helper, T cytotoxic, natural killer and B cells increased significantly by over 20% following HBOT; There was a significant decrease in the number of senescent T helpers by -37.30%±33.04 post-HBOT. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Contradiction: none
Sources: 5
exploratoryInterpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Contradiction: none
Sources: 5
exploratory`fact_id=188537` (`A_core`) — Telomeres length of T helper, T cytotoxic, natural killer and B cells increased significantly by over 20% following HBOT. doi=10.18632/aging.202188
Contradiction: none
Sources: 5
exploratory`fact_id=188541` (`A_core`) — There was a significant decrease in the number of senescent T helpers by -37.30%±33.04 post-HBOT. doi=10.18632/aging.202188
Contradiction: none
Sources: 5
exploratory`fact_id=188542` (`A_core`) — T-cytotoxic senescent cell percentages decreased significantly by -10.96%±12.59 (p=0.0004) post-HBOT. doi=10.18632/aging.202188
Contradiction: none
Sources: 5
exploratory`fact_id=187991` (`A_core`) — HBOT increased the total efficacy rate (TEF) (OR = 4.84, 95% CI = 3.19-7.33, P < 0.00001) doi=10.3389/fnagi.2019.00086
Contradiction: none
Sources: 5